ERYP.PA - ERYTECH Pharma S.A.

Paris - Paris Delayed Price. Currency in EUR
6.14
-0.04 (-0.65%)
As of 12:31PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close6.18
Open6.18
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.10 - 6.23
52 Week Range5.61 - 10.00
Volume8,304
Avg. Volume24,825
Market Cap109.415M
Beta (3Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-2.13
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.53
  • GlobeNewswire14 hours ago

    ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC

    ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2,  evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC). Following the positive Phase 2 results with eryasaspase in second-line metastatic pancreatic cancer, ERYTECH selected  triple-negative breast cancer as the next indication to expand the potential use of eryaspase in solid tumors.

  • A Look At The Intrinsic Value Of ERYTECH Pharma S.A. (EPA:ERYP)
    Simply Wall St.yesterday

    A Look At The Intrinsic Value Of ERYTECH Pharma S.A. (EPA:ERYP)

    Today we will run through one way of estimating the intrinsic value of ERYTECH Pharma S.A. (EPA:ERYP) by projecting...

  • GlobeNewswire3 days ago

    ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies

    LYON, France and CAMBRIDGE, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYTECH) (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells (RBCs), announced today that it has entered into an agreement with SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments in multiple therapeutic areas, to advance novel RBC-based therapeutics for immune modulation. Under the terms of the agreement, ERYTECH has granted to SQZ an exclusive worldwide license to develop antigen-specific immune modulating therapies employing RBC-based approaches. Combining SQZ`s proprietary and versatile cell engineering platform, Cell Squeeze®, with ERYTECH`s intellectual property related to RBC-based therapeutics is intended to allow for the rapid development of a broad pipeline of novel immunomodulatory products addressing multiple indications.

  • GlobeNewswire3 days ago

    ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility

    PRINCETON, N.J. and CAMBRIDGE, Mass. and LYON, France, June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced today the opening of its new Princeton, NJ GMP manufacturing facility. The facility will support production capacity needs for eryaspase, the Company`s lead product candidate for patients in the United States.

  • GlobeNewswire27 days ago

    ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 21, 2019

    LYON, France, May 31, 2019 (GLOBE NEWSWIRE) --  ERYTECH Pharma  (Euronext Paris: ERYP - Nasdaq: ERYP),   a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug ...

  • What Did ERYTECH Pharma S.A.'s (EPA:ERYP) CEO Take Home Last Year?
    Simply Wall St.last month

    What Did ERYTECH Pharma S.A.'s (EPA:ERYP) CEO Take Home Last Year?

    Gil Beyen has been the CEO of ERYTECH Pharma S.A. (EPA:ERYP) since 2013. This report will, first, examine the CEO...

  • GlobeNewswirelast month

    ERYTECH Announces FDA's Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States

    LYON, France and CAMBRIDGE, Mass. , May 13, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells.  The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer. TRYbeCA1 is expected to enroll approximately 500 patients with second-line metastatic pancreatic cancer at more than 120 clinical sites in Europe and the United States.

  • GlobeNewswirelast month

    ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States

    ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells.  The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer. TRYbeCA1 is expected to enroll approximately 500 patients with second-line metastatic pancreatic cancer at more than 120 clinical sites in Europe and the United States.

  • GlobeNewswire2 months ago

    ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019

    Conference call and webcast on Tuesday, May 7 at 2:30 pm CET/8:30 am EDT TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new ...

  • GlobeNewswire2 months ago

    ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors

    LYON, France, May 06, 2019 (GLOBE NEWSWIRE) --  ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...

  • GlobeNewswire2 months ago

    ERYTECH to Host on May 7, 2019 First Quarter Conference Call and Business Update

    Lyon (France), March 2, 2019 - ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances ...

  • Will ERYTECH Pharma S.A.'s (EPA:ERYP) Earnings Grow In The Next Couple Of Years?
    Simply Wall St.3 months ago

    Will ERYTECH Pharma S.A.'s (EPA:ERYP) Earnings Grow In The Next Couple Of Years?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! ERYTECH Pharma S.A.'s (EPA:ERYP) released its most recent earnings update in December 2018, which signalled...

  • GlobeNewswire3 months ago

    Monthly information related to total number of voting rights and shares composing the share capital - March 31, 2019

    LYON, France, April 02, 2019 (GLOBE NEWSWIRE) --                                                                                 Article 223-16 of general regulation of French Autorité des Marchés Financiers ...

  • GlobeNewswire3 months ago

    Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2019

    LYON, France, April 02, 2019 --                                                                                 Article 223-16 of general regulation of French Autorité des.

  • GlobeNewswire3 months ago

    ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting

    Results support the potential for combination of erymethionase with checkpoint inhibition LYON, France and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) --  ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ...

  • GlobeNewswire3 months ago

    ERYTECH Announces Filing of 2018 "Document de Référence" and 2018 Annual Report on Form 20-F

    LYON, France, March 29, 2019 (GLOBE NEWSWIRE) --  ERYTECH Pharma  (Euronext Paris: ERYP - Nasdaq: ERYP),   a clinical-stage biopharmaceutical company developing innovative by encapsulating therapeutic ...

  • GlobeNewswire3 months ago

    ERYTECH Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F

    LYON, France, March 29, 2019 -- ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative by encapsulating.